Aug 24 (Reuters) - The European Commission on Thursday approved U.S. drugmaker Pfizer's (PFE.N) vaccine for respiratory syncytial virus (RSV) to protect both babies and older adults in the ...

In May, the FDA approved GSK’s GSK RSV vaccine, Arexvy, forthe prevention of LRTD caused by RSV in older adults aged 60+ years. This was the first RSV vaccine for older adults to be approved ...

The EU on Friday authorized the sale of a vaccine to protect infants from respiratory syncytial virus (RSV), a disease that in worst cases can lead to pneumonia and bronchiolitis. The bloc-wide ...

If the CDC recommends the vaccine, named Abrysvo, it will be the first vaccine available to protect newborns against RSV, ...

CDC advisors recommend that women in the third trimester of their pregnancy get Pfizer’s Abrysvo RSV vaccine so that their ...

Advisers to the U.S. Centers for Disease Control and Prevention (CDC) are meeting on Friday to discuss recommendations for ...

The Centers for Disease Control and Prevention's independent panel of advisors recommended Pfizer's maternal vaccine that ...

The FDA approved Pfizer's maternal vaccine to protect newborns from RSV. Courtesy Pfizer Still, the vaccine, given from 32 to 36 weeks of gestational age, does not provide long-term protection.

Pfizer PFE announced that the European Commission has approved its new vaccine, Abrysvo, for the prevention of respiratory syncytial virus (RSV) in infants through immunization of their pregnant ...

(Reuters) -The European Commission on Thursday approved U.S. drugmaker Pfizer's vaccine for respiratory syncytial virus (RSV) to protect both babies and older adults in the European Union. The ...

(Reuters) -The European Commission on Thursday approved U.S. drugmaker Pfizer's vaccine for respiratory syncytial virus (RSV) to protect both babies and older adults in the European Union.